Sugi Predict

Sugi Predict / Compounds / SCHEMBL16756387

SCHEMBL16756387

SCHEMBL16756387

Cc1nc2ccc(-c3ccc(N4CCNCC4)nc3)cc2n1Cc1ccccc1OC(F)F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 2/20 0.42
▸ TLR7 Q9NYK1 4/20 0.41
▸ TLR9 Q9NR96 3/20 0.41
▸ TLR8 Q9NR97 3/20 0.41
▸ METAP2 P50579 2/20 0.40
▸ KCNH2 Q12809 5/20 0.39
▸ CACNA1C Q13936 1/20 0.39
▸ ASIC3 Q9UHC3 1/20 0.39
▸ BMPR1B O00238 1/20 0.39
▸ BMPR1A P36894 1/20 0.39
▸ ACVR1B P36896 1/20 0.39
▸ ACVR1 Q04771 1/20 0.39
▸ SLC6A2 P23975 4/20 0.38
▸ SLC6A4 P31645 4/20 0.38
▸ SLC6A3 Q01959 3/20 0.38
▸ JAK2 O60674 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ NMT1 P30419 1/20 0.37
▸ SPHK1 Q9NYA1 1/20 0.37
▸ GRIN1 Q05586 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20278327 0.94 TLR9 (0.42) HTR6TLR7TLR9TLR8METAP2
SCHEMBL24060190 0.94 HTR6 (0.41) HTR6TLR7TLR9TLR8METAP2
SCHEMBL16756602 0.89 TLR7 (0.38) TLR7TLR9TLR8SLC6A4GRIN1
SCHEMBL16756277 0.87 METAP2 (0.38) TLR7METAP2KCNH2SPHK1GRIN1
SCHEMBL16756302 0.87 PPARD (0.40) TLR7SPHK1GRIN1GRIN2B
Hydrochloric Acid SCHEMBL16756445 0.85 PPARD (0.40) KCNH2SPHK1GRIN1GRIN2B
SCHEMBL16756259 0.84 PPARD (0.40) TLR7TLR9TLR8KCNH2SLC6A4
SCHEMBL15560202 0.84 ITGB2 (0.37) TLR7KCNH2GRIN1GRIN2B
SCHEMBL16756580 0.82 TLR7 (0.44) TLR7GRIN1GRIN2B
SCHEMBL16756274 0.82 AOC3 (0.43) HTR6TLR7SPHK1GRIN1GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3995831-A1 ANTIBODY UCB Biopharma SRL (BE) 2022-05-11 — — EP disclosed
EP-3988936-A1 ANTIBODY EPITOPE UCB Biopharma SRL (BE) 2022-04-27 — — EP disclosed
US-20220074947-A1 ANTIBODY EPITOPE UCB Biopharma SRL (BE) 2022-03-10 — — US disclosed
US-20220025033-A1 ANTIBODY EPITOPE UCB Biopharma SRL (BE) 2022-01-27 — — US disclosed
EP-3311171-B1 ANTIBODY EPITOPE UCB Biopharma SRL (BE) 2021-12-01 — — EP disclosed
US-11174311-B2 Antibody against trimeric TNFα complex UCB Biopharma SRL (BE) 2021-11-16 — — US disclosed
EP-3311170-B1 ANTIBODY UCB Biopharma SRL (BE) 2021-10-13 — — EP disclosed
US-20210132079-A1 ANTIBODY UCB Biopharma SRL (BE) 2021-05-06 — — US disclosed
US-10969393-B2 Complexes between anti-TNF antibodies, trimeric TNF proteins and organic molecules binding them UCB Biopharma SRL (BE) 2021-04-06 — — US disclosed
US-20210088530-A1 NOVEL TNFa STRUCTURE FOR USE IN THERAPY UCB Biopharma SRL (BE) 2021-03-25 — — US disclosed
US-10935553-B2 — — 2021-03-02 — — US disclosed
US-10775385-B2 Treatment of autoimmune and inflammatory disorders with asymmetric TNF alpha trimers UCB Biopharma SRL (BE) 2020-09-15 — — US disclosed
US-20190330327-A1 ANTIBODY EPITOPE UCB Biopharma SRL (BE) 2019-10-31 — — US disclosed
US-20180172701-A1 ANTIBODY EPITOPE EMERALD BIOSTRUCTURES, INC. 2018-06-21 — — US disclosed
US-20180172701-A1 ANTIBODY EPITOPE EMERALD BIOSTRUCTURES, INC. 2018-06-21 — — US disclosed
US-20180171008-A1 ANTIBODY UCB Biopharma SRL (BE) 2018-06-21 — — US disclosed
EP-2858983-B1 TNF-ALPHA MODULATING BENZIMIDAZOLES UCB BIOPHARMA SPRL (BE) 2018-04-18 — — EP disclosed
US-9550737-B2 TNF -α modulating benzimidazoles UCB BIOPHARMA SPRL (BE) 2017-01-24 — — US disclosed
WO-2016202415-A1 ANTIBODY EPITOPE UCB BIOPHARMA SPRL (BE) 2016-12-22 — — WO disclosed
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles UCB BIOPHARMA SPRL (BE) 2015-06-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles TNF, TNFRSF1A, NFKBIA HTR6 1299/4885TLR7 3878/4885TLR9 2838/4885
US-20220074947-A1 ANTIBODY EPITOPE TNFRSF9, TNFRSF1A, TNFSF11 HTR6 3848/4885TLR7 1460/4885TLR9 531/4885
US-20180171008-A1 ANTIBODY TNFRSF9, TNFRSF1A, CD40 HTR6 3186/4885TLR7 1850/4885TLR9 604/4885
US-20210088530-A1 NOVEL TNFa STRUCTURE FOR USE IN THERAPY TNFRSF1A, TNFRSF9, CD40 HTR6 2548/4885TLR7 1779/4885TLR9 537/4885
US-10969393-B2 Complexes between anti-TNF antibodies, trimeric TNF proteins and organic molecules binding them TNFRSF1A, TNFRSF9, CD40 HTR6 3820/4885TLR7 3089/4885TLR9 786/4885
US-10775385-B2 Treatment of autoimmune and inflammatory disorders with asymmetric TNF alpha trimers TNFRSF1A, TNFRSF9, CD40 HTR6 2941/4885TLR7 1690/4885TLR9 685/4885
US-20180172701-A1 ANTIBODY EPITOPE TNFRSF9, TNFRSF1A, TNFSF11 HTR6 3848/4885TLR7 1460/4885TLR9 531/4885
US-20220025033-A1 ANTIBODY EPITOPE TNFRSF9, TNFRSF1A, TNFSF11 HTR6 3848/4885TLR7 1460/4885TLR9 531/4885
US-20190330327-A1 ANTIBODY EPITOPE TNFRSF9, TNFRSF1A, TNFSF11 HTR6 3848/4885TLR7 1460/4885TLR9 531/4885
US-10935553-B2 — TNFRSF1A, TNFRSF9, TNFSF11 HTR6 3151/4885TLR7 1872/4885TLR9 729/4885
US-20210132079-A1 ANTIBODY TNFRSF9, TNFRSF1A, CD40 HTR6 3186/4885TLR7 1850/4885TLR9 604/4885
US-11174311-B2 Antibody against trimeric TNFα complex TNFRSF9, TNFRSF1A, TNF HTR6 4199/4885TLR7 1806/4885TLR9 540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.